Top > Search of International Patents > Inhibitor of ischemic disorders

Inhibitor of ischemic disorders

Foreign code F120006293
File No. FU-030P-US
Posted date Mar 12, 2012
Country United States of America
Application number 67512908
Gazette No. 20100217006
Gazette No. 8242302
Date of filing Sep 1, 2008
Gazette Date Aug 26, 2010
Gazette Date Aug 14, 2012
International application number JP2008065680
International publication number WO2009028707
Date of international filing Sep 1, 2008
Date of international publication Mar 5, 2009
Priority data
  • P2007-225021 (Aug 31, 2007) JP
  • 2008WO-JP65680 (Sep 1, 2008) WO
Title Inhibitor of ischemic disorders
Abstract (US8242302)
It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof.
Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion.
It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.
Scope of claims [claim1]
1. A farnesol carboxylic acid ester derivative represented by formula (1):
wherein R1 represents a carboxylic acid residue having a nitrogen substituent selected from the group consisting of an N-acyl amino acid residue, an N-alkyl amino acid residue, an N,N-dialkyl amino acid residue, a pyridinecarboxylic acid residue, and a physiologically acceptable salt thereof, and the physiologically acceptable salt is selected from the group consisting of a hydrohalic acid salt, an alkylsulfonic acid salt, and an acidic sugar salt.
[claim2]
2. An inhibitor of ischemia-reperfusion disorder or a therapeutic agent of cerebral infarction, cerebral edema, or myocardial infarction, comprising, as an active ingredient, at least one substance selected from the group consisting of a farnesol carboxylic acid ester derivative, a pharmacologically acceptable salt thereof, a solvate thereof and a hydrate thereof, wherein said farnesol carboxylic acid ester derivative is represented by formula (2):
wherein R2 represents a carboxylic acid residue having a nitrogen substituent selected from the group consisting of an amino acid residue, an N-acyl amino acid residue, an N-alkyl amino acid residue, an N,N-dialkyl amino acid residue, a pyridinecarboxylic acid residue, and a physiologically acceptable salt thereof, and the physiologically acceptable salt is selected from the group consisting of a hydrohalic acid salt, an alkylsulfonic acid salt, and an acidic sugar salt.
[claim3]
3. The farnesol carboxylic acid ester derivative according to claim 1, wherein R1 is a residue selected from the group consisting of an N-alkyl amino acid residue, an N,N-dialkyl amino acid residue, and a physiologically acceptable salt thereof, and the physiologically acceptable salt is selected from the group consisting of a hydrohalic acid salt, an alkylsulfonic acid salt, and an acidic sugar salt, said alkyl being methyl.
[claim4]
4. The inhibitor of ischemia-reperfusion disorder or the therapeutic agent of cerebral infarction, cerebral edema, or myocardial infarction according to claim 2, wherein R2 is a residue selected from the group consisting of an N-alkyl amino acid residue, an N,N-dialkyl amino acid residue, and a physiologically acceptable salt thereof, and the physiologically acceptable salt is selected from the group consisting of a hydrohalic acid salt, an alkylsulfonic acid salt, and an acidic sugar salt, said alkyl being methyl.
[claim5]
5. A farnesol carboxylic acid ester derivative selected from the group consisting of farnesol sarcosinate, farnesol N-tert-butoxycarbonylglycinate, farnesol N,N-dimethylglycinate, farnesol N,N-dimethyl-beta -alaninate, farnesol N,N-diethyl-beta -alaninate, farnesol N-tert-butoxycarbonylsarcosinate, and hydrochloric acid salts thereof.
[claim6]
6. The inhibitor of ischemia-reperfusion disorder or the therapeutic agent of cerebral infarction, cerebral edema, or myocardial infarction according to claim 2, wherein said farnesol carboxylic acid ester derivative is farnesol N,N-dimethylglycinate or its hydrochloric acid salt.
  • Inventor, and Inventor/Applicant
  • TAKATA JIRO
  • MISHIMA KENICHI
  • NAKASHIMA MANABU
  • IWASAKI KATSUNORI
  • MATSUNAGA KAZUHISA
  • KARUBE YOSHIHARU
  • FUJIWARA MICHIHIRO
  • FUKUOKA UNIVERSITY
IPC(International Patent Classification)

PAGE TOP

close
close
close
close
close
close